Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Randomized, Open-label, Three-arm Study to Evaluate Implementation Strategies for the Delivery of CAB for HIV Pre-exposure Prophylaxis (PrEP) Across Clinical Settings for Adult (≥18 Years) Black cis-and Transgender Women Without HIV Infection Living in the United States Ending the Epidemic (EHE) Territories

NCT05514509 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT05514509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05514509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Randomized, Open-label, Three-arm Study to Evaluate Implementation Strategies for the Delivery of CAB for HIV Pre-exposure Prophylaxis (PrEP) Across Clinical Settings for Adult (≥18 Years) Black cis-and Transgender Women Without HIV Infection Living in the United States Ending the Epidemic (EHE) Territories
Lead sponsor
ViiV Healthcare
Phase
Phase 4
Overall status
Completed
Start date
October 28, 2022
Completion date
September 2, 2025
Enrollment
295 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections